NEW YORK, NY / ACCESSWIRE / June 7, 2017 / U.S. markets fell for the second consecutive day on geopolitical concerns. Inventors appear to be cautious ahead of upcoming events such as the U.K. general election, testimony by former FBI director James Comey and a policy meeting of the European Central Bank, all of which are scheduled for Thursday. The Dow Jones Industrial Average declined 0.23 percent to close at 21,136.23, while the S&P 500 Index dipped 0.28 percent to close at 2,429.33.

"We expect sideways markets over the short-term due to seasonality?summer months tend to be quieter?and investors continue to react to headline news," said Lisa Kopp, head of Traditional Investments Group at U.S. Bank Wealth Management.

RDI Initiates Coverage on:

Celldex Therapeutics, Inc.
https://ub.rdinvesting.com/news/?ticker=CLDX

Pandora Media Inc.
https://ub.rdinvesting.com/news/?ticker=P

Celldex Therapeutics' shares declined 12.45 percent to close at $2.39 a share on Tuesday. The stock traded between $2.37 and $2.73 on volume of 6.14 million shares traded. On June 5th, the company announced data from the Phase 1 portion of a Phase 1/2 dose escalation and cohort expansion study examining the combination of varlilumab, Celldex's CD27 targeting investigational immune-activating antibody, and Bristol-Myers Squibb's anti-PD-1 immunotherapy Opdivo (nivolumab). Shares of Celldex Therapeutics have fallen approximately 32.49 percent year-to-date.

"Combining PD-1 inhibition with a potent T cell activating agent provides the opportunity to broaden the number of patients that benefit from checkpoint blockade," said Dr. Sanborn. "While early, we have evidence that this combination does not add toxicity, can turn some 'immune-cold' tumors hot, and may have clinical benefit, including in some patients who are not likely to respond to monotherapy. Further elucidating the role of intermittent versus chronic T cell activation through the comparison of alternate varlilumab dosing regimens is an essential component of the ongoing Phase 2 study and could be important in optimizing the potential of this combination."

Access RDI's Celldex Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=CLDX

Pandora Media's shares fell 7.70 percent to close at $8.75 a share on Tuesday. The stock traded between $8.73 and $9.47 on volume of 20.80 million shares traded. Verizon is considering a $100 million investment in Pandora if its deal with SiriusXM fails, according to a recent New York Post article. SiriusXM has been in negotiations to acquire Pandora for between $11 and $12 a share, valuing the company at approximately $2.8 billion, two sources familiar with the matter told the New York Post. Shares of Pandora Media have fallen approximately 32.9 percent year-to-date.

Access RDI's Pandora Media Research Report at:
https://ub.rdinvesting.com/news/?ticker=P

Our Actionable Research on Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Pandora Media Inc. (NYSE: P) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com